Dashboard Market News Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Keros Therapeutics Inc banner

Keros Therapeutics Inc
NASDAQ:KROS

Watchlist Manager
Keros Therapeutics Inc Logo
Keros Therapeutics Inc
NASDAQ:KROS
Watchlist
Price: 11.09 USD -0.72% Market Closed
Market Cap: $219.5m
Write Note Create Alert Ask AI

Wall St Price Targets

KROS Price Targets Summary
Keros Therapeutics Inc

Wall Street analysts forecast KROS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KROS is 18.36 USD with a low forecast of 16.16 USD and a high forecast of 26.25 USD.

KROS Lowest Forecast
Wall Street Target
$16.16
46% Upside
KROS Average Forecast
Wall Street Target
$18.36
66% Upside
KROS Highest Forecast
Wall Street Target
$26.25
137% Upside
Lowest Forecast
Price Target
16.16 USD
46% Upside
Average Forecast
Price Target
18.36 USD
66% Upside
Highest Forecast
Price Target
26.25 USD
137% Upside
Keros Therapeutics Inc Competitors:
Price Targets

Revenue
Forecast

70% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
70% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 6 years, the compound annual growth rate for Revenue has been 70%. The projected CAGR for the next 8 years is 6%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 1%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
-3% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
-3% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is -3%.

What are analyst estimates?

Continue KROS Research

Summary
KROS intrinsic value, competitors valuation, and company profile.
DCF Valuation
KROS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KROS stock valuation using valuation multiples.
Wall St Estimates
KROS price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KROS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is KROS's stock price target?
Price Target
18.36 USD

According to Wall Street analysts, the average 1-year price target for KROS is 18.36 USD with a low forecast of 16.16 USD and a high forecast of 26.25 USD.

What is the Revenue forecast for Keros Therapeutics Inc?
Projected CAGR
6%

Over the last 6 years, the compound annual growth rate for Revenue has been 70%. The projected CAGR for the next 8 years is 6%.

What is the Operating Income forecast for Keros Therapeutics Inc?
Projected CAGR
1%

The compound annual growth rate for Operating Income over the next 8 years is 1%.

What is the Net Income forecast for Keros Therapeutics Inc?
Projected CAGR
-3%

The compound annual growth rate for Net Income over the next 8 years is -3%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.